Clinical Trial Update: Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of Felzartamab (MOR202) in immunoglobulin A nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Felzartamab (felzartamab)

Snippet

Sponsor: HI-Bio, A Biogen Company | Conditions: Immunoglobulin A (IgA) Nephropathy | Phase 2 | Status: COMPLETED